HeartSciences Inc Stock Price, News & Analysis

HeartSciences (Nasdaq: HSCS) has strengthened its Scientific Advisory Board with the addition of three distinguished experts in cardiology and AI: Dr. Girish Nadkarni, Dr. Joshua Lampert, and Dr. Akhil Vaid. Dr. Nadkarni, currently serving as Fishberg Professor of Medicine and Director at Mount Sinai, brings extensive expertise with over 375 peer-reviewed publications and 40,000 citations. Dr. Lampert, a cardiac electrophysiologist and Medical Director of Machine Learning at Mount Sinai Fuster Heart Hospital, specializes in heart rhythm disorders and AI applications. Dr. Vaid, an Assistant Professor focusing on AI in healthcare, contributes significant experience in developing AI models for cardiac analysis. These appointments align with HeartSciences' mission to transform ECG technology through AI for earlier heart disease detection.

HeartSciences (NASDAQ: HSCS) has launched its MyoVista Insights™ platform, a cloud-native ECG Management System designed to enhance clinical decision-making and healthcare IT efficiency. The platform features vendor-agnostic integration capabilities for AI-ECG algorithms, a unique prioritization system, and standardized ECG reporting protocols.

Key features include patient-centric longitudinal comparisons, disease progression tracking, and enhanced workflow efficiency. Built on AWS technology stack, MyoVista Insights offers a pay-as-you-go model, reducing implementation and storage costs compared to legacy systems. The platform will integrate both company-developed and third-party AI-ECG algorithms in future releases to help identify patients requiring further cardiac testing earlier.

HeartSciences (HSCS) reported Q3 FY2025 financial results and business updates, highlighting significant progress in AI-powered ECG technology. The company reported no revenues for Q3 FY2025, with cash and cash equivalents of $2.6 million and shareholders' equity of $1.8 million as of January 31, 2025.

Key developments include:

• Final pre-submission meeting with FDA for MyoVista wavECG device in February 2025, with expected FDA clearance submission in H1 2025
• Successful completion of Phase 1 MyoVista Insights cloud-native platform in December 2024
• Pre-validation work completed with Rutgers for low ejection fraction algorithm
• CMS 2025 OPPS final rule inclusion enabling reimbursement upon commercial launch

The company's strategy focuses on modernizing ECG technology through AI-enhanced hardware and software solutions, positioning itself as the only company building next-gen ECG device hardware, device-agnostic cloud-native software, and AI-ECG algorithms.

HeartSciences (Nasdaq: HSCS), an AI-powered medical technology company focused on transforming ECGs/EKGs for earlier heart disease detection, has announced its engagement with Integrous Communications to enhance investor relations. The partnership aims to develop and execute a comprehensive investor communications program, leveraging Integrous' expertise in working with leading medical companies.

Andrew Simpson, Chairman and CEO, emphasized the importance of maintaining robust investor communications as the company continues its mission of transforming cardiovascular screening through AI-ECG technology. Mark Komonoski, Partner of Integrous Communications, expressed enthusiasm about partnering with HeartSciences to communicate its growth strategy and value proposition to the investment community.

HeartSciences (HSCS) reported Q2 FY2025 financial results and business updates. The company is developing next-generation ECG solutions, including the MyoVista® wavECG™ device and MyoVista® Insights™ cloud platform. Phase 1 of MyoVista Insights will be completed by end of 2024, with test site implementations planned for first half of 2025. FDA submission for MyoVista wavECG is expected around end of Q1 2025.

The company reported no revenue in Q2 FY2025, with cash and cash equivalents of $4.1 million and shareholders' equity of $4.0 million as of October 31, 2024. Their AI-ECG algorithms have been included in the CMS 2025 OPPS final rule, enabling reimbursement upon commercial launch.

HeartSciences (NASDAQ: HSCS) announces that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System final rule under APC 5734. This approval will enable outpatient settings to receive $125 reimbursement for HeartSciences' MyoVista® wavECGTM algorithm and MyoVista® InsightsTM low ejection fraction algorithm, pending FDA clearance. The company plans to submit both platforms to the FDA and launch them in 2025.

HeartSciences (Nasdaq: HSCS; HSCSW), an AI-powered medical technology company focused on transforming ECGs/EKGs for earlier heart disease detection, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group and hosted by M-Vest, will take place from October 15 to October 17, 2024.

CEO Andrew Simpson will engage in a fireside chat with analyst Allen Klee on Thursday, October 17th at 10:30 a.m. Eastern Time. Interested parties can register for the event at m-vest.com or through the provided link to reserve a seat.

HeartSciences (Nasdaq: HSCS) reported its Q1 FY2025 financial results and provided a business update. Key highlights include:

• Progress on MyoVista wavECG device and MyoVista Insights cloud platform
• Cash and cash equivalents of $4.3 million and shareholder's equity of $5.9 million
• Secured $1.9 million in non-dilutive financing post-quarter end
• MyoVista Insights AI-ECG algorithm cloud-platform on track for completion by end of 2024
• FDA 510(k) submission for MyoVista wavECG device planned for Q1 2025
• No revenues reported for Q1 FY2025

The company is developing both cloud and device-based AI-ECG solutions, aiming to transform heart disease detection across various healthcare settings.

HeartSciences (NASDAQ: HSCS), an AI-powered medical technology company focusing on early heart disease detection through ECG/EKG transformation, has secured $1.9 million in net proceeds through a non-dilutive financing. This unsecured loan note has an 18-month maturity. Additionally, the company recently extended a $500,000 loan note to September 2025. CEO Andrew Simpson highlighted that these financial moves have extended the company's capital runway by $2.4 million since late August, providing significant opportunities to achieve valuable commercial milestones. The financing comes ahead of upcoming FDA submissions, positioning HeartSciences for potential growth in the medical technology sector.